Connecticut v. Aurobindo Pharma USA, Inc.

District Court, D. Connecticut·Decided April 25, 2025·No. 3:16-cv-02056·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

THE STATE OF CONNECTICUT; THE STATE OF ALASKA; THE STATE OF ARIZONA; THE STATE OF ARKANSAS; THE STATE OF CALIFORNIA; THE STATE OF COLORADO; THE STATE OF DELAWARE; THE DISTRICT OF COLUMBIA; No. 3:16-cv-02056 (MPS) THE STATE OF FLORIDA; THE STATE OF HAWAII; THE STATE OF IDAHO; THE STATE OF ILLINOIS; THE STATE OF INDIANA; THE STATE OF IOWA; THE STATE OF KANSAS; THE COMMONWEALTH OF KENTUCKY; THE STATE OF LOUISIANA; THE STATE OF MAINE; THE STATE OF MARYLAND; THE COMMONWEALTH OF MASSACHUSETTS; THE STATE OF MICHIGAN; THE STATE OF MINNESOTA; THE STATE OF MISSISSIPPI; THE STATE OF MISSOURI; THE STATE OF MONTANA; THE STATE OF NEBRASKA; THE STATE OF NEVADA; THE STATE OF NEW HAMPSHIRE; THE STATE OF NEW JERSEY; THE STATE OF NEW MEXICO; THE STATE OF NEW YORK; THE STATE OF NORTH CAROLINA; THE STATE OF NORTH DAKOTA; THE STATE OF OHIO; THE STATE OF OKLAHOMA; THE STATE OF OREGON; THE COMMONWEALTH OF PENNSYLVANIA; THE COMMONWEALTH OF PUERTO RICO; THE STATE OF RHODE ISLAND; THE STATE OF SOUTH CAROLINA; THE STATE OF TENNESSEE; THE STATE OF UTAH; THE STATE OF VERMONT; THE COMMONWEALTH OF VIRGINIA; THE STATE OF WASHINGTON; THE STATE OF WEST VIRGINIA; THE STATE OF WISCONSIN; and THE STATE OF WYOMING

v.

AUROBINDO PHARMA USA, INC.; ACTAVIS HOLDCO US, INC.; ACTAVIS PHARMA, INC.; APOTEX CORP.; ASCEND LABORATORIES, LLC; CITRON PHARMA, LLC; DR. REDDY’S LABORATORIES, INC.; EMCURE PHARMACEUTICALS, LTD; GLENMARK PHARMACEUTICALS INC., USA; HERITAGE PHARMACEUTICALS, INC.; LANNETT COMPANY, INC.; RAJIV MALIK; MAYNE PHARMA (USA), INC.; SATISH MEHTA; MYLAN PHARMACEUTICALS INC.; TEVA PHARMACEUTICALS USA, INC.; SANDOZ, INC.; SUN PHARMACEUTICAL INDUSTRIES, INC.; and ZYDUS PHARMACEUTICALS (USA), INC. RULING ON JOINT MOTION TO DISMISS STATE-LAW CLAIMS The Defendants have moved under Fed. R. Civ. P. 12(b)(6) to dismiss the state-law claims asserted by the Plaintiffs, the attorneys general of most of the States and several U.S. territories (“the States”), in this sprawling action alleging price-fixing, market allocation, and bid rigging in the sale of generic drugs. ECF No. 602. For the reasons set forth below, I grant in part and deny in part the Defendants’ motion. I. OVERVIEW A. Procedural Background This is one of three cases in which the attorneys general of many states and U.S. territories have sued scores of makers of generic drugs for alleged antitrust violations and unfair trade practices. All three cases were originally filed in this Court but were transferred to the Eastern District of Pennsylvania (the “MDL court”), which was designated by the Judicial Panel on Multidistrict Litigation (the “JPMDL”) to preside over these and other cases involving similar allegations asserted by private parties in a consolidated proceeding. ECF No. 343.1 In April 2024,

1 Unless otherwise indicated, all ECF numbers in this case refer to entries on the docket of this case, not the same case when it was before the MDL court, and each page number refers to the page number shown on the ECF stamp on the top of the cited page, not the page of the relevant brief or pleading designated by the parties. the JPMDL remanded these three cases to this Court, and they were assigned to me. ECF Nos. 345, 353. This case, which the parties refer to as the “Heritage case,” involves allegations that nineteen defendants allocated customers, fixed prices, and rigged bids in the sale of fifteen generic drugs. The Defendants filed the present motion to dismiss with the MDL court on May 31, 2019.

On November 12, 2024, I issued a ruling in one of the parallel actions on a motion to dismiss state-law claims that raise many of the same arguments as those presented here. Connecticut v. Sandoz, Inc., No. 20cv802, 2024 WL 4753308 (D. Conn. Nov. 12, 2024). Although I adopt many of my conclusions from that ruling, the parties in this action have also raised separate and additional claims and arguments, which I address below. B. Allegations The operative complaint in this case, the June 15, 2018 amended complaint (ECF No. 473 on this Court’s docket), spans 191 pages and includes 889 numbered paragraphs.2 It alleges collusion in the pricing, market allocation, and bidding for various generic drugs. The complaint describes a series of conspiracies, and an overarching conspiracy, between makers of generic drug-

related products to collude on price, market allocation, and bids for the business of customers. The complaint alleges that generic drug makers “communicated with each other to determine and agree on how much market share and which customers each competitor was entitled to,” and “then implemented the agreement by either refusing to bid for particular customers or by providing a cover bid they knew would not be successful,” thereby reducing or eliminating competition and allowing them to maintain “supra-competitive prices.” ECF No. 473 ¶ 12. Because the factual

2 By contrast, the operative complaint in Sandoz, No. 20cv802, spans 609 pages and includes 2,123 numbered paragraphs. details of the alleged agreements are not critical to this ruling for reasons I explain below, however, I do not further summarize the complaint here. C. Rule 12(b)(6) While the Defendants have filed previous motions attacking the federal antitrust claims in

this case, this motion targets only the States’ state-law claims and, as discussed below, only certain portions of those claims. In federal court, each complaint must include “a short and plain statement of the claim showing that the pleader is entitled to relief,” Fed. R. Civ. 8(a)(2), and if the complaint “fail[s] to state a claim upon which relief can be granted,” Fed. R. Civ. P. 12(b)(6), the court must dismiss it. In deciding the Defendants’ motion to dismiss under Rule 12(b)(6), I must determine whether the States have alleged “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). I must accept as true the complaint’s factual allegations, id., and must “draw all reasonable

inferences in favor of the non-moving party,” Vietnam Ass’n for Victims of Agent Orange v. Dow Chem. Co., 517 F.3d 104, 115 (2d Cir. 2008). But “threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice” to survive a motion to dismiss. Mastafa v. Chevron Corp., 770 F.3d 170, 177 (2d Cir. 2014) (citation omitted). For the most part, however, the Defendants’ motion does not involve the application of these standards—making it an unusual Rule 12(b)(6) motion. As in the similar motion filed in the parallel Sandoz action, most of the motion does not argue that the States’ allegations under state antitrust and unfair and deceptive practice statutes “fail[ ] to state a claim upon which relief can be granted,” Fed. R. Civ. P. 12(b)(6), or that the price-fixing, bid-rigging, and market allocation allegations do not “plausib[ly]” plead violations of those statutes.

Free access — add to your briefcase to read the full text and ask questions with AI

Connecticut v. Aurobindo Pharma USA, Inc., (D. Conn. 2025).

Connecticut v. Aurobindo Pharma USA, Inc. (Connecticut v. Aurobindo Pharma USA, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Illinois Brick Co. v. Illinois
431 U.S. 720 (Supreme Court, 1977)
California v. ARC America Corp.
490 U.S. 93 (Supreme Court, 1989)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. St. Regis Paper Co.
285 F.2d 607 (Second Circuit, 1960)
State v. First National Bank of Anchorage
660 P.2d 406 (Alaska Supreme Court, 1982)
Stifflear v. Bristol-Myers Squibb Co.
931 P.2d 471 (Colorado Court of Appeals, 1996)
F. Ray Moore Oil Co., Inc. v. State
341 S.E.2d 371 (Court of Appeals of North Carolina, 1986)
Verenes v. Alvanos
690 S.E.2d 771 (Supreme Court of South Carolina, 2010)
In Re Static Random Access Memory (SRAM) Antitrust Litigation
580 F. Supp. 2d 896 (N.D. California, 2008)
Sickles v. Cabot Corp.
877 A.2d 267 (New Jersey Superior Court App Division, 2005)
Clark Oil & Refining Corp. v. Ashcroft
639 S.W.2d 594 (Supreme Court of Missouri, 1982)
In Re Dynamic Random Access Memory (DRAM) Antitrust Litigation
516 F. Supp. 2d 1072 (N.D. California, 2007)
In Re Chocolate Confectionary Antitrust Litigation
602 F. Supp. 2d 538 (M.D. Pennsylvania, 2009)
MacK v. Bristol-Myers Squibb Co.
673 So. 2d 100 (District Court of Appeal of Florida, 1996)
State of NY v. Cedar Park Concrete Corp.
665 F. Supp. 238 (S.D. New York, 1987)
In Re Flash Memory Antitrust Litigation
643 F. Supp. 2d 1133 (N.D. California, 2009)
State v. Jennings
944 A.2d 171 (Supreme Court of Rhode Island, 2008)